Testosterone in Men Over 40: When TRT Is Truly Necessary

The Testosterone Crisis: More Than Just Aging

Testosterone is the primary male androgen governing muscle mass, bone density, cognitive function, mood, and metabolic health. The Massachusetts Male Aging Study documented a decline of 1.6% per year in total testosterone after age 40. More concerning, Travison et al. (JCEM, 2007) identified a population-level decline: men in the 2000s had 15-20% lower testosterone than same-age men in the 1980s, independent of aging.

Hypogonadism affects 20-40% of men over 45 (Mulligan et al., International Journal of Clinical Practice, 2006). Symptoms are nonspecific — fatigue, decreased libido, depression, visceral obesity, brain fog — and frequently misattributed to normal aging or stress.

Total vs Free Testosterone: Why One Lab Is Not Enough

Approximately 98% of circulating testosterone is protein-bound: 60-70% to sex hormone-binding globulin (SHBG) and 25-35% to albumin. Only 1-3% circulates freely. Biological effects depend primarily on free and bioavailable (albumin-bound + free) testosterone.

SHBG increases with age, hyperthyroidism, liver disease, and certain medications. A man with total testosterone of 450 ng/dL but elevated SHBG may have clinically low free testosterone and significant symptoms.

Essential diagnostic panel: - Total testosterone (morning, fasting, measured twice) - Free testosterone (calculated or equilibrium dialysis) - SHBG - LH, FSH (to differentiate primary vs secondary hypogonadism) - Estradiol - Prolactin - PSA (prostate-specific antigen) - CBC (hemoglobin, hematocrit) - Lipid panel, HbA1c, fasting insulin

Primary vs Secondary Hypogonadism

Primary hypogonadism — testicular failure: elevated LH/FSH with low testosterone. Causes include Klinefelter syndrome, orchitis, trauma, varicocele, cryptorchidism, and chemotherapy.

Secondary (central) hypogonadism — hypothalamic or pituitary dysfunction: low or normal LH/FSH with low testosterone. Causes include obesity, chronic stress, obstructive sleep apnea, opioids, pituitary adenoma, and hyperprolactinemia.

In obese men with insulin resistance, functional secondary hypogonadism is common. Corona et al. (Endocrine Reviews, 2020) demonstrated that 10-15% weight loss can normalize testosterone without TRT.

TRT Formulations: Injections, Gels, and Pellets

### Intramuscular Injections (Testosterone Cypionate/Enanthate)

The most studied and cost-effective option. Standard dosing: 100-200 mg every 1-2 weeks. Drawback: peak-trough fluctuations ("roller coaster" effect). Subcutaneous micro-injections every 3-4 days (50-80 mg) provide more stable levels and are increasingly preferred.

### Transdermal Gels (AndroGel, Testogel)

Daily application to shoulders, abdomen, or inner thighs. Provide stable 24-hour levels. Concerns: skin-to-skin transfer risk to partners and children; absorption variability up to 30% between patients.

### Subcutaneous Pellets (Testopel)

Implanted every 3-6 months under buttock skin. Most stable hormone delivery without daily procedures. Handelsman et al. (Clinical Endocrinology, 2017) reported 85-90% patient satisfaction. Drawback: invasive insertion, inability to rapidly discontinue if side effects arise.

### DHEA (Dehydroepiandrosterone)

An adrenal prohormone converted to testosterone and estrogens. Dosage: 25-50 mg/day. A meta-analysis in JCEM (2005) showed modest free testosterone increases in men over 60. Not a substitute for TRT in frank hypogonadism, but useful for borderline cases.

Safety Monitoring on TRT

Per Endocrine Society guidelines (Bhasin et al., JCEM, 2018):

Every 3-6 months: - Total and free testosterone (target: 450-700 ng/dL) - Hematocrit (stop TRT if >54%: thrombosis risk) - PSA (stop if rise >1.4 ng/mL over 12 months) - Estradiol (target: 20-40 pg/mL; if elevated — aromatase inhibitor)

Annually: - Lipid panel - Bone densitometry (if osteopenia present) - Mood and quality-of-life assessment (ADAM or AMS questionnaire)

Natural Testosterone Optimization

Before initiating TRT, modifiable factors must be addressed:

Sleep. A meta-analysis in Sleep Medicine Reviews (2019): restricting sleep to 5 hours reduces testosterone by 10-15%. Optimal: 7-9 hours of uninterrupted sleep.

Zinc. Zinc deficiency is a leading cause of low testosterone. Dosage: 30-50 mg/day zinc picolinate. Prasad et al. (Nutrition, 1996) demonstrated a doubling of testosterone with deficiency correction.

Vitamin D3. Pilz et al. (Hormone and Metabolic Research, 2011) RCT: 3,332 IU daily for one year raised total testosterone from 10.7 to 13.4 nmol/L. Target 25(OH)D: 40-60 ng/mL.

Resistance Training. Meta-analysis in Sports Medicine (2022): resistance exercise raises testosterone 15-30% within 48 hours. Prioritize compound multi-joint movements.

Stress Management. Chronic stress raises cortisol, which suppresses GnRH and testosterone. Ashwagandha: a systematic review in Journal of Ethnopharmacology (2023) confirms 14-17% testosterone increase.

Frequently Asked Questions

Does TRT cause prostate cancer? A meta-analysis in Medicine (Boyle et al., 2016) and Morgentaler (JAMA, 2023) found no increased prostate cancer risk in men without pre-existing malignancy. TRT is contraindicated in untreated prostate cancer.

Does TRT affect fertility? Yes. Exogenous testosterone suppresses FSH/LH, causing azoospermia in 40-60% of men. If fatherhood is planned, clomiphene or hCG are alternatives.

At what age should testosterone be checked? With symptoms — at any age. Screening is recommended from age 40 in men with obesity, type 2 diabetes, chronic fatigue, or decreased libido.

Can low testosterone be managed without TRT? At levels of 250-350 ng/dL, a 3-6 month trial of lifestyle optimization (sleep, zinc, D3, exercise) is reasonable. Below 250 ng/dL with pronounced symptoms, TRT is typically necessary.

*This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.*

🌀

Cardiovascular Safety of TRT: TRAVERSE and Beyond

Cardiovascular safety has been the principal regulatory concern since the 2015 FDA class label warning. The TRAVERSE trial, a randomized placebo-controlled non-inferiority study in 5,246 men aged 45–80 with hypogonadism and either established cardiovascular disease or high baseline risk, found no increased incidence of the composite primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke over a mean follow-up of 33 months (hazard ratio 0.96; 95% CI 0.78–1.17) [PMID: 37381268^[1]]. This is the largest dedicated cardiovascular outcomes trial of testosterone replacement to date and supersedes earlier observational signals.

However, TRAVERSE identified statistically higher rates of three secondary events in the testosterone group: pulmonary embolism, atrial fibrillation, and acute kidney injury. The pulmonary embolism finding is consistent with prior pharmacovigilance data showing increased venous thromboembolism risk in the first six months of therapy [PMID: 27042810^[2]]. Men with prior unprovoked VTE, known thrombophilia (factor V Leiden, prothrombin G20210A, antiphospholipid syndrome), or active malignancy should be considered relatively contraindicated, or therapy should be coordinated with anticoagulation. Atrial fibrillation incidence was approximately 3.5% versus 2.4%; the mechanism is uncertain but may relate to atrial structural remodeling and erythrocytosis-mediated changes in viscosity.

The earlier signal from the 2013 Vigen retrospective Veterans Affairs cohort, which reported a 29% relative increase in death, MI, or stroke, has been criticized for unadjusted confounding and miscoded female patients [PMID: 24489673^[3]]. Similarly, the 2014 Finkle case-only analysis of post-prescription MI cannot establish causality. The TOM trial (Testosterone in Older Men with Mobility Limitations) was stopped early in 2010 for a numerical excess of cardiovascular events, but the trial was underpowered and used 100 mg topical doses in a frail population not generalizable to standard TRT candidates.

Practical implication: in men without recent acute coronary syndrome (within 6 months), unstable heart failure (NYHA III–IV), or recent stroke, TRT does not appear to increase major adverse cardiovascular events. Baseline cardiovascular risk should still be quantified (ASCVD score, lipid panel, blood pressure) and optimized before initiation. A baseline ECG is reasonable in men over 60 or with risk factors to document pre-existing atrial fibrillation. Hematocrit must be monitored as the principal modifiable thrombotic mediator, addressed in the next section.

🌀

Erythrocytosis on TRT: Mechanism, Monitoring, and Management

Erythrocytosis is the most common dose-limiting adverse effect, occurring in 11–25% of treated men depending on formulation, with the highest rates in intramuscular regimens producing supraphysiologic peaks [PMID: 23625883^[4]]. Testosterone stimulates erythropoiesis through three mechanisms: direct suppression of hepcidin (increasing iron availability), stimulation of erythropoietin production by the renal interstitium, and a downward reset of the EPO-hemoglobin set point. The result is a dose-dependent rise in hemoglobin and hematocrit, typically peaking at 3–9 months.

The Endocrine Society 2018 clinical practice guideline recommends discontinuation or dose reduction when hematocrit exceeds 54%. The 54% threshold derives from observational data linking polycythemia vera to thrombotic events; the absolute thrombotic risk in TRT-induced erythrocytosis at 52–54% is less well characterized but the cautionary threshold is retained.

Practical management algorithm: at hematocrit 52–54%, reduce dose by 25–50%, extend injection interval, or switch from intramuscular to transdermal preparation (gels produce hematocrit elevations 2–3 percentage points lower on average). At hematocrit above 54%, hold therapy until hematocrit returns below 50%, then resume at reduced dose. Therapeutic phlebotomy of 450–500 mL removes approximately 200 mg of iron and lowers hematocrit by 3 percentage points; it is appropriate as a bridge but should not be used to permit ongoing supraphysiologic dosing. Coordinate with a blood bank for autologous donation when possible.

Risk modifiers include smoking, obstructive sleep apnea, chronic obstructive pulmonary disease, and high altitude residence, each of which independently raises baseline hematocrit. Obstructive sleep apnea screening (STOP-BANG, polysomnography if indicated) is warranted before initiation in men with elevated BMI or daytime somnolence, as untreated OSA both predisposes to erythrocytosis and is itself worsened by testosterone in a subset of patients. Hydration status should be confirmed before any borderline hematocrit reading is acted upon, and ferritin should be checked annually in men receiving repeated phlebotomy to avoid iatrogenic iron deficiency, which can paradoxically worsen fatigue and obscure the symptomatic benefit of therapy.

🌀

Estradiol Management and the Aromatase Inhibitor Question

Approximately 0.2–0.3% of circulating testosterone is converted to estradiol by aromatase, principally in adipose tissue, brain, and bone. Estradiol mediates several physiologic effects historically attributed to testosterone, including bone mineral density maintenance, suppression of visceral adiposity, lipid profile, and libido. Factorial-design studies have demonstrated that estradiol independently regulates fat accumulation and sexual function in men, and that suppression of estradiol below approximately 20 pg/mL produces metabolic and sexual adverse effects independent of testosterone level.

Empiric aromatase inhibitor (AI) co-prescription with TRT is therefore not recommended. The reflex use of anastrozole 0.5–1 mg twice weekly that proliferated in commercial men's health clinics has no supporting RCT evidence in eugonadal-range estradiol and carries documented risks: reduced bone mineral density, dyslipidemia, arthralgia, and possible cognitive effects.

Indications for anastrozole 0.25–0.5 mg twice weekly are narrow: (1) symptomatic gynecomastia or persistent breast tenderness with estradiol above 50–60 pg/mL on sensitive LC-MS/MS assay; (2) refractory water retention with confirmed elevated estradiol; (3) obese men with baseline aromatase excess in whom weight loss is not feasible. The target is estradiol 20–35 pg/mL, not suppression below 20 pg/mL. Standard immunoassays for estradiol are unreliable in men at low concentrations; LC-MS/MS is preferred.

If gynecomastia is established and tender (typically within the first 6 months of therapy), tamoxifen 10–20 mg daily for 3–6 months is more effective than anastrozole at reversing glandular tissue, with stronger evidence in the breast cancer prevention literature applied off-label here. Once fibrosis develops beyond 12 months, pharmacologic reversal is unlikely and surgical referral is appropriate.

Monitoring on AI therapy should include estradiol at 6 weeks after dose changes, bone densitometry at baseline and every 2 years, and lipid panel annually. AI dosing should be titrated by symptoms and LC-MS/MS estradiol, not empiric schedules. Patients should be counseled that estradiol within 20–35 pg/mL is physiologic and beneficial; the goal is not zero. A useful clinical pearl: men who report worsening joint pain, depressed mood, or low libido after starting an AI are typically over-suppressed, and the AI should be stopped or halved before adjusting testosterone.

🌀

Fertility Preservation: hCG, Clomiphene, and Enclomiphene

Exogenous testosterone suppresses hypothalamic GnRH and pituitary LH/FSH, reducing intratesticular testosterone by 95% or more and inducing azoospermia in 40–65% of users within 4 months [PMID: 24074889^[5]]. For men who wish to preserve fertility or whose hypogonadism is functional and secondary, three alternatives bypass the suppression problem.

Human chorionic gonadotropin (hCG) acts as an LH analogue, stimulating Leydig cell testosterone production and maintaining spermatogenesis. Typical dosing is 500–1500 IU subcutaneously two to three times weekly. hCG can be used as monotherapy or in combination with low-dose testosterone to maintain testicular volume and fertility during TRT [PMID: 19414536^[6]]. Combination protocols typically use testosterone cypionate 100 mg weekly plus hCG 500 IU twice weekly.

Clomiphene citrate is a selective estrogen receptor modulator that blocks hypothalamic estrogen feedback, raising endogenous LH and FSH. Typical dosing is 25 mg every other day or daily; total testosterone rises by 200–300 ng/dL in responders [PMID: 23625883^[4]]. It is FDA-approved for female infertility and used off-label in men. Side effects include mood changes and rare visual disturbances. Enclomiphene, the trans-isomer of clomiphene, has a more favorable side-effect profile in early studies but is not FDA-approved.

For men discontinuing TRT to attempt fatherhood, a post-TRT restart protocol combines hCG 1500 IU three times weekly for 4 weeks followed by clomiphene 25–50 mg daily plus tamoxifen 20 mg daily, with semen analysis every 3 months. Recovery to baseline spermatogenesis typically occurs within 6–12 months but ranges from 3 to 24 months; predictors of delayed recovery include longer duration of TRT, older age, smaller baseline testicular volume, and concurrent anabolic steroid history [PMID: 24074889^[5]]. Cryopreservation of sperm before TRT initiation is advisable for any man under 45 who has not completed family planning.

Monitoring during fertility-preservation protocols includes semen analysis at baseline and every 3 months, total testosterone, LH, FSH, and estradiol every 6–12 weeks, and PSA and hematocrit on the same schedule as standard TRT. hCG monotherapy at 1500–3000 IU twice weekly is sufficient to restore mid-range testosterone in many men with intact testicular function and avoids the spermatogenic suppression of exogenous testosterone entirely. Aromatization on hCG is more pronounced than on testosterone esters because intratesticular aromatase is preserved, and clinically significant gynecomastia is reported in 5–10% of long-term users; this is the principal trade-off versus standard TRT.

🌀

Pre-TRT Screening and Contraindications

Before initiating therapy, the following baseline panel should be documented: two morning total testosterone measurements (08:00–10:00, fasting, separated by 1–4 weeks), free testosterone by equilibrium dialysis or calculated from total testosterone, SHBG, and albumin, LH, FSH, prolactin (to exclude pituitary adenoma if LH/FSH are inappropriately normal or low), estradiol by LC-MS/MS, PSA in men over 40, complete blood count with hematocrit, comprehensive metabolic panel, lipid panel, HbA1c, ferritin and iron studies, vitamin D, and TSH.

Absolute contraindications: untreated prostate cancer or breast cancer, hematocrit above 54% at baseline, severe untreated obstructive sleep apnea, severe lower urinary tract symptoms (IPSS above 19), uncontrolled congestive heart failure (NYHA class IV), recent (within 6 months) myocardial infarction, stroke, or unstable angina, active venous thromboembolism, and male-factor infertility with active conception plans (use hCG or clomiphene instead).

Relative contraindications requiring shared decision-making: PSA above 4 ng/mL or rising velocity above 0.75 ng/mL/year without urologic clearance, prior thrombophilia or unprovoked VTE, IPSS 12–19, BPH requiring catheterization, polycythemia vera or other myeloproliferative disorder, history of atrial fibrillation, and age above 80 in the absence of clear symptomatic indication. A digital rectal exam and PSA should be performed at baseline in men over 40, with urology referral for any abnormality before initiation [PMID: 30602527^[7]].

Functional secondary hypogonadism in obese men deserves separate emphasis: weight loss of 10–15% restores testosterone in the majority and should precede TRT consideration unless symptoms are severe or testosterone is below 200 ng/dL [PMID: 28359097^[8]]. Glucagon-like peptide-1 receptor agonists, bariatric surgery, and structured lifestyle interventions all produce measurable testosterone recovery proportional to weight lost.

A pragmatic pre-initiation checklist: confirm two morning testosterone values below age-adjusted thresholds, document at least three classic symptoms (low libido, erectile dysfunction, decreased morning erections, reduced muscle mass, fatigue, depressed mood), exclude reversible causes (medications, opioids, glucocorticoids, hyperprolactinemia, hemochromatosis, hypothyroidism), discuss fertility plans and offer sperm banking if relevant, optimize OSA and obesity, and obtain written informed consent that explicitly addresses cardiovascular risk, erythrocytosis, infertility, and the long-term commitment of therapy. The decision to start TRT is reversible only with a recovery interval; this should be made clear at the first visit, not after suppression has occurred.